ARTICLE | Deals
AstraZeneca, Hong Kong-based CSPC in deal for dyslipidemia therapy
Deals report: Recordati acquires Enjaymo from Sanofi, and updates from BioMarin-Camp4, Editas-DRI and more
October 7, 2024 11:59 PM UTC
AstraZeneca is paying Hong Kong-based CSPC $100 million up front for rights to a preclinical lipid-lowering therapy with a mechanism that could complement a PCSK9 inhibitor the European pharma is already developing.
The deal will give AstraZeneca plc (LSE:AZN; NASDAQ:AZN) rights to YS2302018, a small molecule designed to prevent formation of Lp(a). Elevated levels of that form of LDL are a risk factor for cardiovascular disease...